The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RPRX | +49.47% | +7.33% | +1.42% | -3% |
| S&P | +12.65% | +91.73% | +13.89% | +115% |
Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $609.29M | 7.9% |
| Gross Profit | $608.01M | 0.0% |
| Gross Margin | 99.79% | 0.0% |
| Market Cap | $15.25B | 20.3% |
| Market Cap / Employee | $154.05M | 0.0% |
| Employees | 99 | 11.2% |
| Net Income | $444.21M | -44.9% |
| EBITDA | $428.43M | -41.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $938.94M | -1.2% |
| Accounts Receivable | $888.97M | 12.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.58B | 29.8% |
| Short Term Debt | $380.00M | -61.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.09% | -2.7% |
| Return On Invested Capital | 5.93% | -2.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $703.52M | -1.6% |
| Operating Free Cash Flow | $703.52M | -1.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 13.30 | 12.70 | 15.69 | 20.17 | 82.31% |
| Price to Book | 1.66 | 2.00 | 2.29 | 2.40 | 30.80% |
| Price to Sales | 6.64 | 7.95 | 8.79 | 8.40 | 13.52% |
| Price to Tangible Book Value | -1.41 | -1.70 | -1.84 | -1.57 | 0.79% |
| Price to Free Cash Flow TTM | 6.22 | 7.57 | 9.45 | 9.26 | 35.47% |
| Enterprise Value to EBITDA | 69.38 | 51.69 | 146.76 | 72.26 | 98.44% |
| Free Cash Flow Yield | 16.1% | 13.2% | 10.6% | 10.8% | -26.19% |
| Return on Equity | 12.7% | 16.6% | 15.9% | 11.5% | -34.64% |
| Total Debt | $7.61B | $7.62B | $8.02B | $8.96B | 17.82% |
No podcast episodes available.
RPRX earnings call for the period ending June 30, 2022.
RPRX earnings call for the period ending March 31, 2022.
RPRX earnings call for the period ending December 31, 2021.
RPRX earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
